United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 250 mg - carefully consider the potential benefits and risks of naproxen, ec-naproxen, anaprox, anaprox ds or naproxen suspension and other treatment options before deciding to use naproxen, ec-naproxen, naproxen sodium or naproxen sodium ds. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation ). naproxen as naproxen, ec-naproxen, naproxen sodium or naproxen sodium ds is indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. naproxen as naproxen, naproxen sodium and naproxen sodium ds is also indicated: - for relief of the

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - chlordiazepoxide hcl/clidinium bromide is indicated to control emotional and somatic factors in gastrointestinal disorders. chlordiazepoxide hcl/clidinium bromide may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. chlordiazepoxide hcl/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. the more severe withdrawal symptoms have usually been limited to tho

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - amiodarone hydrochloride is indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. - cardiogenic shock. - sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia leading to syncope without a functioning pacemaker. - known hypersensitivity to the drug or to any of its components, including iodine. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventricular arrh

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone acetate 30 mg - hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of anorectum, and pruritus ani. hydrocortisone acetate suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components. drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of anorectum, and pruritus ani. hydrocortisone acetate suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components. drug abuse and dependence have not been reported in patients treated with hydrocortisone acetate suppositories.

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - selenium sulfide (unii: z69d9e381q) (selenium sulfide - unii:z69d9e381q) - selenium sulfide 2.3% shampoo is a liquid antiseborrheic, antifungal preparation useful for the treatment of seborrheic dermatitis of the scalp, dandruff and tinea versicolor. urea hydrates and is useful for conditions such as dry scalp. selenium sulfide 2.3% shampoo is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals, llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules are contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsules are contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen delayed-release tablets are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naproxen delayed-release tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9)] . - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)]. - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)] . risk summary use of nsaids, including naproxen delayed-release tablets can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal

Australia - English - Department of Health (Therapeutic Goods Administration)

camerons herbs & homoeopathics - passiflora incarnata, quantity: 20 mg (equivalent: passiflora incarnata, qty 100 mg); avena sativa, quantity: 25 mg (equivalent: avena sativa, qty 250 mg); nicotinamide, quantity: 10 mg; hypericum perforatum, quantity: 111.67 mg (equivalent: hypericum perforatum, qty 670 mg); dibasic potassium phosphate, quantity: 1 mg (equivalent: phosphorus, qty 177.9 microgram; equivalent: potassium, qty 448.9 microgram); ziziphus jujuba, quantity: 15 mg (equivalent: ziziphus jujuba, qty 60 mg); humulus lupulus, quantity: 33.34 mg (equivalent: humulus lupulus, qty 250 mg); hydrastis canadensis, quantity: 6.25 mg (equivalent: hydrastis canadensis, qty 25 mg); thiamine hydrochloride, quantity: 5 mg; pyridoxine hydrochloride, quantity: 500 microgram (equivalent: pyridoxine, qty 411 microgram); scutellaria baicalensis, quantity: 25 mg (equivalent: scutellaria baicalensis, qty 100 mg); magnesium phosphate pentahydrate, quantity: 2 mg (equivalent: phosphorus, qty 350.8 microgram; equivalent: magnesium, qty 413.2 microgram); bacopa monnieri, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; acacia; maltodextrin; povidone; colloidal anhydrous silica; calcium hydrogen phosphate dihydrate - relieve irritability ; soothe/calm nerves ; decrease/reduce/relieve symptoms of stress ; decrease/reduce/relieve nervous tension/unrest ; enhance/promote/increase refreshing sleep

United States - English - NLM (National Library of Medicine)

cameron pharmaceuticals - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride is indicated for the production of spinal anesthesia for procedures requiring two to three hours. spinal anesthesia with tetracaine hydrochloride is contraindicated in patients with known hypersensitivity to tetracaine hydrochloride or to drugs of a similar chemical configuration (ester-type local anesthetics), or aminobenzoic acid or its derivatives; and in patients for whom spinal anesthesia as a technique is contraindicated. the decision as to whether or not spinal anesthesia should be used for an individual patient should be made by the physician after weighing the advantages with the risks and possible complications. contraindications to spinal anesthesia as a technique can be found in standard reference texts, and usually include generalized septicemia, infection at the site of injection, certain diseases of the cerebrospinal system, uncontrolled hypotension, etc.